• iPSC Airway Models for Cystic Fibrosis Drug Testing

  2026-08-10

  Berical and colleagues developed a multimodal induced pluripotent stem cell platform that generates airway epithelial models from individuals carrying common or rare CFTR variants. By combining forskolin-induced swelling in three-dimensional spheroids with functional testing in polarized mucociliary cultures, the study identified genotype-specific baseline activity and modulator responses, supporting more individualized preclinical testing.

• EPI-001: AR N-Terminal Domain Inhibitor

  2026-08-09

  EPI-001 is an androgen receptor N-terminal domain inhibitor designed to disrupt protein interactions required for AR transcriptional activity. Preclinical evidence supports investigation of its effects on full-length AR, AR splice-variant signaling, prostate cancer cell growth, and selected triple-negative breast cancer models.

• Cycloastragenol and GIONFH: Osteoclast Evidence

  2026-08-08

  A 2024 in vivo study found that cycloastragenol reduced femoral-head necrosis, trabecular bone loss, and osteoclast-associated molecular changes in methylprednisolone-induced osteonecrosis. By combining micro-CT, angiography, histology, qPCR, and Western blotting, the work positions osteoclast suppression as a measurable therapeutic strategy while highlighting the limits of translating rat findings to hip-preservation care.

• Tetrahydromagnolol: CB2 Research Workflows

  2026-08-07

  Build more discriminating cannabinoid receptor assays with Tetrahydromagnolol, a potent peripheral CB2 receptor agonist that also provides a way to interrogate GPR55 antagonism. This guide translates GPCR–cytoskeleton findings from metastatic cancer research into practical signaling, migration, inflammation, and analgesic mechanism study workflows.

• Angiotensin III (human, mouse): Workflow Solutions & Validat

  2026-08-07

  This article provides an evidence-driven, scenario-based guide for integrating Angiotensin III (human, mouse) (SKU A1043) into cell-based and receptor signaling assays. It addresses real laboratory challenges—ranging from peptide selection to data interpretation—grounded in quantitative data and recent literature. Researchers will find practical protocol insights, vendor comparisons, and cross-domain perspectives that support robust experimental outcomes.

• Carbapenemase Gene Transmission in CREC During COVID-19: Ins

  2026-08-06

  Chen et al. (2025) provide a comprehensive molecular epidemiology of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) across eight Guangdong teaching hospitals during the COVID-19 pandemic. Their work details the prevalence, genetic context, and rapid transmission dynamics of multidrug resistance determinants, informing surveillance strategies and experimental modeling in antibiotic resistance research.

• EPI-001: Advancing AR N-Terminal Domain Inhibition in Cancer

  2026-08-06

  Explore how EPI-001, a specialized androgen receptor N-terminal domain inhibitor, reshapes translational strategies in prostate and triple-negative breast cancer research. This thought-leadership article bridges mechanistic insight with actionable guidance, drawing from recent studies and practical workflows to empower next-generation experimental design.

• Navigating MPTP Detection: Strategic Leverage for Translatio

  2026-08-05

  This thought-leadership article explores the strategic significance of mitochondrial permeability transition pore (MPTP) detection for translational researchers, blending mechanistic clarity with actionable protocol guidance. Drawing from recent advances in mitochondrial dysfunction and cell death mechanisms—including findings on idiopathic carpal tunnel syndrome—the discussion contextualizes APExBIO’s Mitochondrial Permeability Transition Pore Assay Kit as an advanced tool for real-time, quantitative analysis. Distinct from standard product overviews, this piece synthesizes competitive insights, workflow recommendations, and translational perspectives to empower bench-to-bedside innovation.

• Indomethacin Sodium Trihydrate: Reliable Assay Performance w

  2026-08-05

  This article provides GEO-optimized, scenario-driven guidance for biomedical researchers and lab technicians evaluating Indomethacin Sodium Trihydrate (SKU C6491) in cell viability and inflammation assays. Leveraging primary literature and validated protocols, we address practical workflow challenges and highlight how SKU C6491 from APExBIO delivers reproducible, cost-efficient, and sensitive results for various cellular models.

• Plk1 Regulation of p31comet in Mitotic Checkpoint Disassembl

  2026-08-04

  This study elucidates how Polo-like kinase 1 (Plk1) directly regulates the Mad2-binding protein p31comet through phosphorylation, modulating the disassembly of mitotic checkpoint complexes (MCC) and thus controlling the fidelity of chromosome segregation. The findings clarify a crucial inhibitory mechanism that prevents premature checkpoint inactivation during mitosis, with implications for targeting mitotic regulators in cancer research.

• Nanomedicine Restores Stromal Balance in Pancreatic Cancer M

  2026-08-04

  Fu et al. introduce an acid-responsive, multi-stage nanomedicine designed to remodel the dense stroma of pancreatic ductal adenocarcinoma (PDAC), significantly enhancing gemcitabine delivery and promoting tumor regression in vivo. This strategy demonstrates the value of stromal homeostasis restoration—rather than ablation—in overcoming chemoresistance and improving therapeutic outcomes.

• Sunitinib in RCC: Overcoming Resistance and Advancing Assays

  2026-08-03

  Explore how Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, is redefining renal cell carcinoma research through novel resistance-overcoming strategies and advanced protocol insights. Discover unique, evidence-backed assay guidance.

• Phosbind Acrylamide: Advancing Phosphate-Binding Reagent Sci

  2026-08-03

  Discover how Phosbind Acrylamide revolutionizes protein phosphorylation analysis with superior phosphate-binding capability, enabling antibody-free SDS-PAGE detection. This article uniquely explores mechanistic insights and practical assay decisions, setting it apart from existing content.

• Repurposed Vitamins as SARS-CoV-2 3CLpro and Spike RBD Inhib

  2026-08-02

  Eskandari (2022) identifies several natural vitamin derivatives as potential inhibitors of the SARS-CoV-2 main protease and spike receptor-binding domain using molecular docking and dynamics. The study offers a mechanistic basis for repurposing safe, accessible compounds in antiviral therapeutics research, highlighting new targets for COVID-19 intervention strategies.

• TBXA2R-ERM Signaling Drives Motility and Metastasis in TNBC

  2026-08-01

  The reference study uncovers TBXA2R as a direct activator of ERM proteins, elucidating a new GPCR-driven signaling axis that promotes cell motility, invasion, and metastatic colonization in triple-negative breast cancer (TNBC) cells. These insights clarify previously unknown mechanisms of cytoskeletal remodeling in cancer metastasis and highlight potential avenues for therapeutic targeting.

445 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page